Conversion to resection after chemotherapy in metastatic colorectal cancer (CRC) patients with various organ metastases has not yet been investigated in detail. Multivariate analyses showed that single organ metastasis and liver metastasis and the use of biologic agents correlated with successful conversion therapy. KaplanMeier analyses suggested that the survival of patients who received successful conversion therapy was similar to that of stage IV CRC patients initially treated with curative surgery. Background: Systemic chemotherapy increases the possibility of resection in patients with initially unresectable colorectal cancer (CRC), especially patients with hepatic metastasis. However, the predictive factors and prognosis of conversion to resection after chemotherapy in patients with various organ metastases remain largely unknown. Patients and Methods: We reviewed the data from metastatic CRC (mCRC) patients who had received oxaliplatin-or irinotecan-based systemic chemotherapy from 2005 to 2016. The predictors for conversion to surgery were assessed by multivariate analyses. Cancer-free survival and overall survival after the initiation of treatment were compared between patients who had undergone successful conversion therapy and those who had undergone surgery first for resectable stage IV CRC. Results: Of 99 mCRC patients receiving first-line chemotherapy, 23 underwent secondary surgical resection. Single organ metastasis, the presence of liver metastases, and the use of biologic agents were independent predictors of successful conversion therapy. The long-term survival of patients who underwent successful secondary surgery did not differ significantly from that of the 112 patients with resectable stage IV CRC who had undergone surgery first. Conclusion: Liver metastases and single organ metastasis were more likely to be resected after chemotherapy than were other metastatic lesions in mCRC. The use of biologic agents contributed to the increased conversion rate. Successful conversion resulted in outcomes similar to those of resectable stage IV CRC.
Introduction
Colorectal cancer (CRC) is 1 of the leading causes of morbidity and mortality worldwide. 1 Approximately 25% of CRC patients will have metastatic diseases at the initial diagnosis, and 50% will develop metastatic disease metachronously. 2 Unless resection is feasible, systemic chemotherapy constitutes the main therapeutic option for these patients. In the past decade, prominent advances in chemotherapy with cytotoxic drugs, combined with molecular targeting agents, have contributed to the prolonged survival of patients with initially unresectable or metastatic CRC (mCRC) 2, 3 and have further render metastases resectable in a subset of patients. 4, 5 Previous studies investigating "conversion" to resection have mostly focused on CRC with liver-limited metastasis. 4, 5 In contrast, fewer studies have examined conversion therapy for CRC patients with unresectable lesions involving extrahepatic and/or multiple distant organs. Moreover, the factors associated with conversion and the long-term outcomes of conversion therapy have not yet been investigated in detail. We analyzed the clinicopathologic parameters of who had received systemic chemotherapy for mCRC with the aim of identifying the factors associated with conversion to resection. We also compared the prognosis of the patients who had undergone secondary surgery with that of patients with resectable stage IV CRC.
Patients and Methods

Patients and Data Retrieval
We retrospectively reviewed the data from stage IV CRC patients who were treated in our department from June 2005 to April 2016. Of these, we selected the mCRC patients with an initial diagnosis of unresectable disease who had received FOLFOX (5-fluorouracil , folinic acid, oxaliplatin), CapeOX (capecitabine, oxaliplatin), SOX (S-1, oxaliplatin), or FOLFIRI (5-FU, folinic acid, irinotecan) as first-line chemotherapy. For comparison, the data from stage IV CRC patients with resectable metastases were also analyzed. Patients who received neoadjuvant chemotherapy for resectable disease were excluded. In all eligible patients, data regarding age, sex, Eastern Cooperative Oncology Group performance status, serum tumor markers (eg, carcinoembryonic antigen and carbohydrate antigen 19-9) just before the initiation of chemotherapy, location (ie, right-sided colon, left-sided colon, or rectum), and histologic grade of the primary tumor and metastasized organs were documented. The KRAS status in exon 2 was analyzed when available.
The local ethics committees in the University of Tokyo approved the study protocol [reference no. 3252-(3)], and the study complied with the standards of the Declaration of Helsinki in its revised version of 1975 and later amendments. All patients provided written informed consent. [10] [11] [12] The choice of cytotoxic drugs and targeted agents was dependent on the physicians' discretion; however, cetuximab and panitumumab were exclusively used for CRC with wild-type KRAS. Dose reductions and the cessation of chemotherapy were considered according to the patient's condition and preference. To evaluate the tumor response, computed tomography scans were performed before chemotherapy and every 2 to 3 months thereafter during treatment. When elevations in serum tumor markers were noted in an accelerated manner or symptoms suggestive of disease progression appeared, computed tomography scans and other imaging modalities such as magnetic resonance imaging and positron emission tomography were also performed. In each case, the best response was graded using the Response Evaluation Criteria In Solid Tumors, version 1.1. 13 Resectability, Conversion, and Follow-up Resectability was dependent on whether it was possible to completely resect the metastatic lesions while preserving adequate function of the target organ and without sacrificing adjacent critical organs. In our institute, resectability was assessed jointly in conferences or cancer board meetings by multiple doctors who specialized in gastrointestinal, hepatobiliary, or pulmonary surgery and/or radiology. Conversion was defined as macroscopically complete removal (R0 or R1 resection) for all lesions disseminated from the CRC and/or the primary tumor per se that had initially been deemed unresectable. Surgical complications were graded using the Clavien-Dindo classification.
Chemotherapy Regimen and Radiologic Evaluation
14 Postoperative treatments such as adjuvant chemotherapy, palliative chemotherapy, radiotherapy, surgical resection, and other local treatments for recurrent disease were reviewed from the medical records. Recurrence-free survival was defined as the interval from complete removal of the cancer and the date of recurrence. Overall survival (OS) was defined as the interval between the initiation of any treatment and death from any cause. Surviving patients were censored at the last point of direct or indirect patient contact.
Results
Profiles of mCRC Patients
A total of 99 patients (59 men; mean age, 61 years) received systemic chemotherapy for mCRC during the study period. The baseline characteristics of the patients are listed in Table 1 . Most patients had a good performance status. Rectal cancer was predominant (55%). A differentiated histologic type was noted in 86% of the patients. Multiple organs were involved in > 50% of cases; the most frequently involved organ was the liver (62%), followed by the lung (39%) and distant lymph nodes (35%). Asymptomatic primary tumors were not resected in 40% of patients before chemotherapy. Approximately 80% of patients had elevated carcinoembryonic antigen levels (> 5 ng/mL), and carbohydrate antigen 19-9 was elevated (> 37 U/mL) in 57% of patients before chemotherapy. The KRAS status in exon 2 was analyzed in 68 patients (69%); of these, 26 harbored mutations in the gene.
Chemotherapy Regimen
The regimens selected as first-line chemotherapy are listed in Table 2 . Most patients (97%) received an oxaliplatin-based cytotoxic drug combination as the backbone chemotherapy regimen. Targeted biologic agents were used for 60% of patients. Bevacizumab was administered to 28 patients, and cetuximab or panitumumab was given to 31 patients with CRC with wild-type KRAS.
Best Response, Conversion, and Details of Surgery
As the best response, the tumor volumes were reduced from baseline in 54 patients, including 7 with stable disease according to e92 -Clinical Colorectal Cancer March 2018
Conversion to Resection for Unresectable or Metastatic CRC the Response Evaluation Criteria In Solid Tumors. Of these, the responses were deemed sufficient for resection in 23 patients (43%). These 23 patients underwent surgical resection after a median of 4.6 months (range, 1.5-30.4 months) of systemic chemotherapy. Forty surgical procedures were performed on these patients, including primary tumor resection in 13, hepatic resection in 21, pulmonary resection in 5, and peritoneal resection in 1. Of these 40 procedures, 12 (30%) were accompanied by postoperative complications classified as Clavien-Dindo system grade 2. These complications included 6 surgical site infections, 5 systemic noninfectious complications, and 1 nonsurgical infection.
Predictive Factors for Conversion
To identify the clinicopathologic predictors of successful conversion in mCRC, we first conducted a univariate analysis using the logistic regression model. Single organ metastasis, the existence of liver metastasis, no lung metastasis, no peritoneal metastasis, and the use of biologic agents were associated with a greater possibility of conversion (Table 3) . We then performed multivariate analyses to identify the independent predictors of conversion using these parameters. Single organ metastasis, the existence of liver metastasis, and the use of biologic agents were independent predictive factors of conversion (single organ metastasis: odds ratio, 22.64, P < .0001; liver metastasis: odds ratio, 60.60, P < .0001; biologic agents: odds ratio, 56.86, P < .0001; Table 4 ).
Comparisons of Prognosis Between Conversion Therapy mCRC Patients and Resectable Stage IV CRC Patients
To elucidate the prognostic effect of conversion, we compared the long-term outcomes of patients who had undergone secondary surgery with those of patients with resectable stage IV CRC treated by surgery first. The profiles of the 2 groups are presented in Table 5 . The surgery-first group had fewer patients with multiple organ metastases (11% vs. 30%; P ¼ .013) and distant lymph nodal involvement (6% vs. 22%; P ¼ .048) compared with the conversion group. Moreover, fewer patients in the conversion group had received adjuvant chemotherapy than in the surgery-first group (43% vs. 67%; P ¼ .034; Table 6 ). The combination of oxaliplatin and 5-FU was the major common regimen in both groups (60% and 67%, respectively). In patients with recurrence, similar treatments were administered to the surgery-first and conversion groups ( Table 6) .
As shown in Figure 1 , 44% of patients undergoing secondary surgery after chemotherapy were estimated to survive recurrence free for 2 years after the complete removal of cancer. The difference from that of the surgery-first CRC patients (28%) was not statistically significant (P ¼ .79). OS after the start of the treatment was also similar between the 2 groups (3-year OS rate, 66% for conversion group and 77% for surgery-first group; P ¼ .22; Figure 2 ). 
Hiroaki Nozawa et al
Clinical Colorectal Cancer March 2018 -e93
Discussion
In the era of cytotoxic drug combinations and biologic agents, the sequential integration of effective chemotherapy and surgical resection has emerged as a new strategy for improving the prognosis of patients with mCRC. In the current treatment paradigm, the characterization of patients with a high possibility of conversion to resection is an important issue. The predictive factors for conversion to hepatectomy were previously addressed in patients with initially unresectable colorectal liver metastases. 15 We attempted to investigate the predictive factors of successful conversion therapy for patients with mCRC and various organ involvement using multivariate analyses. A recent study reported that greater conversion rates to resectability could be achieved using intensified chemotherapy with triplet cytotoxic drugs (ie, FOLFOXIRI [5-FU, folinic acid, oxaliplatin, irinotecan]) in liver-limited mCRC. 16, 17 In targeted biologic associations, the BOXER (bevacizumab, oxaliplatin, xeloda in unresectable liver metastases) study and the First BEAT (bevacizumab expanded access trial) study showed that the addition of bevacizumab to key cytotoxic drug combinations increased the Excluding cases for which data were not available. conversion rates in liver-limited mCRC. 18, 19 Similarly, anti-EGFR targeting biologic agents were shown to contribute to an increased conversion rate in patients with KRAS wild-type CRC liver-limited metastases. 5, 20 However, when disseminated lesions are not confined to the liver, a paucity of clinical trials is available to demonstrate the superior conversion rates of anti-EGFR antibodyincluding therapy to backbone cytotoxic drugs alone. 21 A combined analysis of data from the First BEAT and NO16966 trials failed to show additional effects of bevacizumab in the resectability of CRC with any distant metastases. 18 Hence, the use and effects of biologic drugs have been controversial in conversion therapy for mCRC.
Our findings showing that the use of bevacizumab, cetuximab, or panitumumab predicted for high resectability could usher in these targeted antibodies as key components of conversion therapy for mCRC.
In the present study, liver metastasis and single organ metastasis were significant predictive factors for secondary surgical resection after first-line chemotherapy for mCRC. These results appear to reflect the liver as the predominant target organ in previous studies of conversion therapy for mCRC.
In analyses of the long-term prognosis, mCRC patients undergoing surgery after first-line systemic chemotherapy exhibited more advanced disease such as multiple organ and distant lymph node metastases than did resectable stage IV CRC patients treated by surgery first (Table 5) . Nevertheless, the conversion group experienced recurrence-free survival and OS similar to those of the surgery-first group (Figures 1 and 2) . Therefore, our results emphasize the long-term substantial benefits of conversion therapy.
Our study had several limitations. Because of its retrospective nature, potential biases were present in the selection of chemotherapy regimens. Our study cohort included patients lacking information on KRAS status because the cost of the gene analysis was not covered by the national health insurance system in Japan until 2010. Moreover, the extended RAS status and other genetic mutations such as BRAF were not examined in many patients for similar reasons. In addition, we did not assess cases of conversion after second-line chemotherapy or other treatment modalities. We also did not consider the number, size, or anatomic site of the lesions within the metastasized organs. Furthermore, the background and postoperative chemotherapy regimens of the patients were not matched in the comparison of prognoses between the conversion therapy and surgery-first groups.
Conclusion
We have demonstrated that single organ metastasis and liver metastasis are significant factors associated with a high conversion rate to secondary resection after systemic chemotherapy for initially unresectable CRC. In combination with cytotoxic drugs, the use of appropriate types of biologic drugs should be considered to increase the possibility of resection. Successful conversion therapy can be expected to reverse the progression of CRC.
Clinical Practice Points
Conversion to resection after chemotherapy was previously mainly investigated in initially unresectable CRC patients with liver-limited metastasis. Conversion therapy for mCRC patients with various organ metastases had yet to be characterized in detail. We have demonstrated that single organ metastasis, liver metastasis, and the use of biologic drugs correlated with an increased probability of conversion to resection in mCRC patients with various organ metastases. Kaplan-Meier survival analyses showed that the survival of patients who received successful conversion therapy was similar to that of initially resectable stage IV colorectal cancer patients who had undergone curative surgery first. Therefore, conversion therapy could reverse the progression of mCRC. 
